Which of these do you expect to create the biggest buzz in 2018?

Biosimilar availability: 11.0%

Clawbacks or DIR fees: 27.8%

Copay cards for generic drugs: 5.6%

Mergers in healthcare: 50.0%

Outcomes-based agreements: 5.6%